NCT06267742

Clinical Trial to Evaluate MDW for Early Detection of Sepsis

Name: Clinical Trial NCT06267742
Creator: Beckman Coulter, Inc.
Keywords: Sepsis, Complete Blood Count (CBC) with Differential, diagnostic test, clinical trial, China

Clinical Trial to Evaluate Early Sepsis Indicator Monocyte Distribution Width (MDW) for Early Detection of Sepsis or Developing Sepsis

Beckman Coulter, Inc.·ClinicalTrials.gov·diagnostic testRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Sepsis
Drug/Device/Intervention: Complete Blood Count (CBC) with Differential
Study type: Observational
Intervention type: diagnostic test

Sponsor & location

Primary sponsor: Beckman Coulter, Inc.
Location: Beijing,Chengdu,Hangzhou, China

Timeline & enrollment

Phase: N/A
Start date: Jun 23, 2022
End date: Sep 30, 2024
Enrollment: 2200 participants

Primary outcome

sensitivity, specificity

Summary

This study is intended to clinically verify Monocyte Distribution Width (MDW) parameter of DxH 900 Hematology Analyzer for use in early detection and risk assessment of sepsis, severe sepsis, and septic shock in critically ill patients in Emergency Department (ED). This study is also aimed to provide study supporting data for the product to be marketed in China.

ICD-10 classifications

Other sepsisSepsis, unspecifiedOther specified sepsisCandidal sepsisPuerperal sepsis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06267742
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06267742 through Pure Global AI's free database. This phase not specified trial is sponsored by Beckman Coulter, Inc. and is currently Recruiting. The study focuses on Sepsis. Target enrollment is 2200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.